+Added: LEGAL PROCEEDINGS
On October 2, 2018, Contract Pharmacal Corp.
2 unchanged sentences
(“WMI”), at 110 Plant Avenue, Hauppauge, New
−Removed: In the action, Contract Pharmacal sought damages for an amount in excess of $1,000,000 for our failure to make the entire premises
−Removed: available by what it claims was the Sublease commencement date.
−Removed: On July 8, 2021, the Court denied Contract Pharmacal’s motion for
−Removed: summary judgement.
−Removed: In the Order, the court granted Contract Pharmacal’s Motions to drop its claim for specific performance and to
−Removed: amend its Complaint to reduce its claim for damages to $700,000.
+Added: Contract Pharmacal sought damages for an amount in excess of $1,000,000 for our failure to make the entire premises available by
+Added: what it claims was the Sublease commencement date.
+Added: On July 8, 2021, the Court denied Contract Pharmacal’s motion for summary judgement.
+Added: In the Order, the court granted Contract Pharmacal’s Motions to drop its claim for specific performance and to amend its Complaint
+Added: to reduce its claim for damages to $700,000.
Subsequently, Contract Pharmacal moved to amend its Complaint.
−Removed: and the Court denied the request to amend the Complaint.
+Added: We opposed and the Court denied
+Added: the request to amend the Complaint.
Contract Pharmacal filed a Motion to reargue which the Court denied on November 30, 2021.
−Removed: On March 10, 2022, Contract Pharmacal filed an appeal to the Court’s decision with the Appellate Division.
−Removed: The Appellate
−Removed: Division upheld the denial of Contract Pharmacal’s motion for summary judgement and upheld the denial of its motion to amend its
−Removed: On March 29, 2023, Contract Pharmacal filed a motion to reargue the appeal previously denied by the Appellate Division.
−Removed: dispute the validity of the claims asserted by Contract Pharmacal, continue to believe we have a meritorious defense to those claims and
−Removed: intend to dispute the validity of the claim asserted by Contract Pharmacal.
−Removed: From time to time
−Removed: we may be engaged in various lawsuits and legal proceedings in the ordinary course of our business.
−Removed: We are currently not aware of any
−Removed: legal proceedings the ultimate outcome of which, in our judgment based on information currently available, would have a material adverse
−Removed: effect on our business, financial condition or operating results.
−Removed: There are no proceedings in which any of our directors, officers or
−Removed: affiliates, or any registered or beneficial stockholder of our common stock, is an adverse party or has a material interest adverse to
−Removed: our interest.
−Removed: SAFETY DISCLOSURES
+Added: 10, 2022, Contract Pharmacal filed an appeal to the Court’s decision with the Appellate Division.
+Added: The Appellate Division upheld
+Added: the denial of Contract Pharmacal’s motion for summary judgement and upheld the denial of its motion to amend its Complaint.
+Added: 28, 2024, Contract Pharmacal filed a motion to reargue the appeal previously denied by the Appellate Division.
+Added: Pending a decision by the
+Added: Appellate Division the Trial Court has adjourned the case.
+Added: Regardless of the decision by the Appellate Division, Contract Pharmacal
+Added: will be required to file an amended complaint.
+Added: We have consistently disputed the validity of the claims asserted by Contract Pharmacal
+Added: and continue to believe we have a meritorious defense to those claims based on, among other items, language in the Sublease.
+Added: to continue to dispute the validity of the claim asserted by Contract Pharmacal.
+Added: From time to time we may be engaged in various
+Added: lawsuits and legal proceedings in the ordinary course of our business.
+Added: We are currently not aware of any legal proceedings the ultimate
+Added: outcome of which, in our judgment based on information currently available, would have a material adverse effect on our business, financial
+Added: condition or operating results.
+Added: There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial
+Added: stockholder of our common stock, is an adverse party or has a material interest adverse to our interest.
+Added: MINE SAFETY DISCLOSURES
Not applicable.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.